iTeos Therapeutics Inc.

6.32
-0.38 (-5.74%)
At close: Mar 28, 2025, 3:59 PM
6.48
2.53%
After-hours: Mar 28, 2025, 05:14 PM EDT

Company Description

Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients.

The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2 clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity.

Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts.

iTeos Therapeutics Inc.
iTeos Therapeutics Inc. logo
Country United States
IPO Date Jul 24, 2020
Industry Biotechnology
Sector Healthcare
Employees 173
CEO Dr. Michel Detheux Ph.D.

Contact Details

Address:
321 Arsenal Street
Cambridge, Massachusetts
United States
Website https://www.iteostherapeutics.com

Stock Details

Ticker Symbol ITOS
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001808865
CUSIP Number 46565G104
ISIN Number US46565G1040
Employer ID 00-0000000
SIC Code 2836

Key Executives

Name Position
Dr. Michel Detheux Ph.D. President, Chief Executive Officer & Director
Matthew Gall Chief Financial Officer
Matthew A. Call M.B.A. Chief Operating Officer
Adi Osovsky Executive Vice President of Legal
Dr. David Feltquate M.D., Ph.D. Chief Medical Officer
Dr. Yvonne McGrath Ph.D. Chief Scientific Officer
Philippe Brantegem Executive Vice President of Human Resources

Latest SEC Filings

Date Type Title
Mar 11, 2025 4 Filing
Mar 11, 2025 4 Filing
Mar 11, 2025 4 Filing
Mar 11, 2025 4 Filing
Mar 05, 2025 S-8 Filing
Mar 05, 2025 10-K Annual Report
Feb 14, 2025 SCHEDULE 13G/A [Amend] Filing
Jan 13, 2025 8-K Current Report
Dec 06, 2024 4 Filing
Nov 21, 2024 SC 13G Statement of acquisition of beneficial ownership b...